GPR40 is partially required for insulin secretion following activation of β 3-adrenergic receptors

Molecular and Cellular Endocrinology

Volumn 325, Issue 1-2, 2010, Pages 18-25

  Pang, Zhen ^a   Wu, Nancy ^a   Zhang, Xin ^a   Avallone, Roberta ^b   Croci, Tiziano ^b   Dressler, Holly ^a   Palejwala, Vaseem ^a   Ferrara, Pascual ^a   Tocci, Michael J ^a   Polites, H Gregory ^a  

^a SANOFI   (France)

^b NONE   (Italy)

Author keywords

3 adrenoceptor; CAMP reporter; GPR40; Insulin secretion; Lipolysis; Pancreatic islet

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; BETA 3 ADRENERGIC RECEPTOR; CYCLIC AMP; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; INSULIN; SODIUM CHLORIDE;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG TARGETING; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; INSULIN RELEASE; INSULIN RESPONSE; ISOLATED PANCREAS ISLET; KNOCKOUT MOUSE; LIPOLYSIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TIME; WILD TYPE;

ADRENERGIC BETA-AGONISTS; ANIMALS; BODY WEIGHT; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, BETA-3; RECEPTORS, G-PROTEIN-COUPLED; TETRAHYDRONAPHTHALENES;

EID: 77954384873     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.04.014     Document Type: Article

References (48)

1. Alemzadeh R., Tushaus K.M. Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide. Endocrinology 2004, 145:5476-5484.
2. Anthony A. Review article: beta 3-adrenoceptor agonists--future anti-inflammatory drugs for the gastrointestinal tract?. Aliment Pharmacol. Ther. 1996, 10:859-863.
3. Anthony A., Schepelmann S., Guillaume J.L., Strosberg A.D., Dhillon A.P., Pounder R.E., Wakefield A.J. Localization of the beta(beta)3-adrenoceptor in the human gastrointestinal tract: an immunohistochemical study. Aliment Pharmacol. Ther. 1998, 12:519-525.
4. Anthony A., Sim R., Guillaume J.L., Strosberg A.D., Dhillon A.P., Pounder R.E., Wakefield A.J. Beta(beta)3-adrenergic receptors in human pancreatic islet and duodenal somatostatin neuroendocrine cells. Aliment Pharmacol. Ther. 2000, 14:579-585.
5. Atef N., Lafontan M., Double A., Helary C., Ktorza A., Penicaud L. A specific beta 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur. J. Pharmacol. 1996, 298:287-292.
6. Bollheimer L.C., Skelly R.H., Chester M.W., McGarry J.D., Rhodes C.J. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J. Clin. Invest. 1998, 101:1094-1101.
7. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., Ellis C., Elshourbagy N.A., Goetz A.S., Minnick D.T., Murdock P.R., Sauls H.R., Shabon U., Spinage L.D., Strum J.C., Szekeres P.G., Tan K.B., Way J.M., Ignar D.M., Wilson S., Muir A.I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 2003, 278:11303-11311.
8. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., McCoy D.C., Kenakin T.P., Andrews J.L., Ammala C., Fornwald J.A., Ignar D.M., Jenkinson S. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 2006, 148:619-628.
9. Brownlie R., Mayers R.M., Pierce J.A., Marley A.E., Smith D.M. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem. Soc. Trans. 2008, 36:950-954.
10. Cellek S., Thangiah R., Bassil A.K., Campbell C.A., Gray K.M., Stretton J.L., Lalude O., Vivekanandan S., Wheeldon A., Winchester W.J., Sanger G.J., Schemann M., Lee K. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 2007, 133:175-183.
11. Claustre Y., Leonetti M., Santucci V., Bougault I., Desvignes C., Rouquier L., Aubin N., Keane P., Busch S., Chen Y., Palejwala V., Tocci M., Yamdagni P., Didier M., Avenet P., Le Fur G., Oury-Donat F., Scatton B., Steinberg R. Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience 2008, 156:353-364.
12. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
13. Elia M., Livesey G. Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. World Rev. Nutr. Diet. 1992, 70:68-131.
14. Flodgren E., Olde B., Meidute-Abaraviciene S., Winzell M.S., Ahren B., Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 2007, 354:240-245.
15. Gavrilova O., Marcus-Samuels B., Reitman M.L. Lack of responses to a beta3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 2000, 49:1910-1916.
16. Granneman J.G., Lahners K.N., Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol. Pharmacol. 1991, 40:895-899.
17. Grujic D., Susulic V.S., Harper M.E., Himms-Hagen J., Cunningham B.A., Corkey B.E., Lowell B.B. Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J. Biol. Chem. 1997, 272:17686-17693.
18. Himms-Hagen J., Cui J., Danforth E., Taatjes D.J., Lang S.S., Waters B.L., Claus T.H. Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats. Am. J. Physiol. 1994, 266:R1371-R1382.
19. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
20. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., Ogi K., Hosoya M., Tanaka Y., Uejima H., Tanaka H., Maruyama M., Satoh R., Okubo S., Kizawa H., Komatsu H., Matsumura F., Noguchi Y., Shinohara T., Hinuma S., Fujisawa Y., Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
21. Kebede M., Alquier T., Latour M.G., Semache M., Tremblay C., Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008, 57:2432-2437.
22. Kim H., Pennisi P.A., Gavrilova O., Pack S., Jou W., Setser-Portas J., East-Palmer J., Tang Y., Manganiello V.C., Leroith D. Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1227-E1236.
23. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301:406-410.
24. Lan H., Hoos L.M., Liu L., Tetzloff G., Hu W., Abbondanzo S.J., Vassileva G., Gustafson E.L., Hedrick J.A., Davis H.R. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008, 57:2999-3006.
25. Landi M., Croci T., Manara L. Similar atypical beta-adrenergic receptors mediate in vitro rat adipocyte lipolysis and colonic motility inhibition. Life Sci. 1993, 53:PL297-302.
26. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., Lin D.C., Poitout V. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
27. Li D.S., Yuan Y.H., Tu H.J., Liang Q.L., Dai L.J. A protocol for islet isolation from mouse pancreas. Nat. Protoc. 2009, 4:1649-1652.
28. Liu X., Perusse F., Bukowiecki L.J. Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am. J. Physiol. 1998, 274:R1212-R1219.
29. Manara L., Badone D., Baroni M., Boccardi G., Cecchi R., Croci T., Giudice A., Guzzi U., Landi M., Le Fur G. Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br. J. Pharmacol. 1996, 117:435-442.
30. Muzzin P., Revelli J.P., Kuhne F., Gocayne J.D., McCombie W.R., Venter J.C., Giacobino J.P., Fraser C.M. An adipose tissue-specific beta-adrenergic receptor. Molecular cloning and down-regulation in obesity. J. Biol. Chem. 1991, 266:24053-24058.
31. Nahmias C., Blin N., Elalouf J.M., Mattei M.G., Strosberg A.D., Emorine L.J. Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J. 1991, 10:3721-3727.
32. Perfetti R., Hui H., Chamie K., Binder S., Seibert M., McLenithan J., Silver K., Walston J.D. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity. J. Mol. Endocrinol. 2001, 27:133-144.
33. Pettersson U.S., Henriksnas J., Jansson L. Reversal of high pancreatic islet and white adipose tissue blood flow in type 2 diabetic GK rats by administration of the beta3-adrenoceptor inhibitor SR-59230A. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E490-E494.
34. Regard J.B., Kataoka H., Cano D.A., Camerer E., Yin L., Zheng Y.W., Scanlan T.S., Hebrok M., Coughlin S.R. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J. Clin. Invest. 2007, 117:4034-4043.
35. Salehi A., Flodgren E., Nilsson N.E., Jimenez-Feltstrom J., Miyazaki J., Owman C., Olde B. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 2005, 322:207-215.
36. Schaeffer P., Bernat A., Arnone M., Manara L., Gallas J.F., Dol-Gleizes F., Millet L., Grosset A., Herbert J.M. Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice. Eur. J. Pharmacol. 2006, 529:172-178.
37. Smith S.J., Zhang H., Clermont A.O., Powers A.C., Kaufman D.B., Purchio A.F., West D.B. In vivo monitoring of pancreatic beta-cells in a transgenic mouse model. Mol. Imaging 2006, 5:65-75.
38. Stein D.T., Stevenson B.E., Chester M.W., Basit M., Daniels M.B., Turley S.D., McGarry J.D. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest. 1997, 100:398-403.
39. Stemmelin J., Cohen C., Terranova J.P., Lopez-Grancha M., Pichat P., Bergis O., Decobert M., Santucci V., Francon D., Alonso R., Stahl S.M., Keane P., Avenet P., Scatton B., le Fur G., Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008, 33:574-587.
40. Steneberg P., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005, 1:245-258.
41. Susulic V.S., Frederich R.C., Lawitts J., Tozzo E., Kahn B.B., Harper M.E., Himms-Hagen J., Flier J.S., Lowell B.B. Targeted disruption of the beta 3-adrenergic receptor gene. J. Biol. Chem. 1995, 270:29483-29492.
42. Tan C.P., Feng Y., Zhou Y.P., Eiermann G.J., Petrov A., Zhou C., Lin S., Salituro G., Meinke P., Mosley R., Akiyama T.E., Einstein M., Kumar S., Berger J.P., Mills S.G., Thornberry N.A., Yang L., Howard A.D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57:2211-2219.
43. Tsujii S., Bray G.A. Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Res. 1992, 587:226-232.
44. Vasina V., Abu-Gharbieh E., Barbara G., de Giorgio R., Colucci R., Blandizzi C., Bernardini N., Croci T., Del Tacca M., de Ponti F. The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol. Motil. 2008, 20:1030-1041.
45. Weyer C., Gautier J.F., Danforth E. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab. 1999, 25:11-21.
46. Williams C.A., Shih M.F., Taberner P.V. Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A. Br. J. Pharmacol. 1999, 128:1586-1592.
47. Yoshida T. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Am. J. Clin. Nutr. 1992, 55:237S-241S.
48. Yoshida T., Sakane N., Wakabayashi Y., Umekawa T., Kondo M. Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific beta 3-adrenoceptor agonist, in yellow KK mice. Life Sci. 1994, 54:491-498.